Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 338% % 111%
Debt-to-equity 114% % -12%
Return On Equity -685% % -5.5%
Return On Assets -319% % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 916,968 shares -95%
Common Stock, Shares, Outstanding 833,683 shares -95%
Entity Public Float $7,300,000 USD 66%
Common Stock, Value, Issued $84 USD -95%
Weighted Average Number of Shares Outstanding, Basic 833,683 shares 5146%
Weighted Average Number of Shares Outstanding, Diluted 833,683 shares 5146%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $11,584,948 USD 23%
General and Administrative Expense $5,460,952 USD 4.3%
Operating Income (Loss) $17,045,900 USD -16%
Nonoperating Income (Expense) $10,088,024 USD -3770%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $27,133,924 USD -82%
Earnings Per Share, Basic 787 USD/shares 96%
Earnings Per Share, Diluted 787 USD/shares 96%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,835,916 USD 51%
Assets, Current $4,751,048 USD 32%
Property, Plant and Equipment, Net $19,908 USD -68%
Operating Lease, Right-of-Use Asset $37,731 USD -92%
Assets $5,226,682 USD 33%
Contract with Customer, Liability, Current $0 USD
Liabilities, Current $2,967,828 USD 30%
Liabilities $3,800,703 USD 66%
Retained Earnings (Accumulated Deficit) $84,419,882 USD -47%
Stockholders' Equity Attributable to Parent $1,425,979 USD -14%
Liabilities and Equity $5,226,682 USD 33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,096,707 USD 21%
Net Cash Provided by (Used in) Financing Activities $8,854,797 USD 45%
Net Cash Provided by (Used in) Investing Activities $3,836 USD 70%
Common Stock, Shares Authorized 290,000,000 shares 0%
Common Stock, Shares, Issued 833,683 shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,758,090 USD 168%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,835,916 USD 51%
Interest Paid, Excluding Capitalized Interest, Operating Activities $5,653 USD -32%
Deferred Tax Assets, Valuation Allowance $16,134,185 USD 27%
Deferred Tax Assets, Gross $16,134,185 USD 27%
Operating Lease, Liability $38,291 USD -92%
Depreciation $13,443 USD -58%
Payments to Acquire Property, Plant, and Equipment $3,836 USD -70%
Lessee, Operating Lease, Liability, to be Paid $38,291 USD -92%
Property, Plant and Equipment, Gross $362,387 USD -11%
Operating Lease, Liability, Current $38,291 USD -91%
Lessee, Operating Lease, Liability, to be Paid, Year One $38,291 USD -91%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,027 USD -93%
Deferred Tax Assets, Operating Loss Carryforwards $8,893,509 USD 51%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $228,000 USD -35%
Operating Lease, Payments $232,520 USD -33%
Additional Paid in Capital $85,845,777 USD 46%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $42,012 USD -63%
Interest Expense $17,221 USD -67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%